Cromwell Holdings LLC boosted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 4.5% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 830 shares of the pharmaceutical company’s stock after purchasing an additional 36 shares during the quarter. Cromwell Holdings LLC’s holdings in Vertex Pharmaceuticals were worth $386,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also bought and sold shares of the company. Brookstone Capital Management boosted its stake in shares of Vertex Pharmaceuticals by 11.1% during the first quarter. Brookstone Capital Management now owns 2,368 shares of the pharmaceutical company’s stock valued at $990,000 after purchasing an additional 237 shares in the last quarter. Future Financial Wealth Managment LLC bought a new stake in Vertex Pharmaceuticals during the 1st quarter valued at $42,000. Wealthcare Advisory Partners LLC increased its holdings in shares of Vertex Pharmaceuticals by 4.6% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 3,218 shares of the pharmaceutical company’s stock valued at $1,345,000 after acquiring an additional 141 shares during the period. 180 Wealth Advisors LLC raised its position in shares of Vertex Pharmaceuticals by 42.9% in the 1st quarter. 180 Wealth Advisors LLC now owns 976 shares of the pharmaceutical company’s stock worth $408,000 after acquiring an additional 293 shares in the last quarter. Finally, Kathmere Capital Management LLC lifted its position in shares of Vertex Pharmaceuticals by 9.9% during the first quarter. Kathmere Capital Management LLC now owns 577 shares of the pharmaceutical company’s stock valued at $241,000 after buying an additional 52 shares during the last quarter. 90.96% of the stock is owned by institutional investors.
Vertex Pharmaceuticals Stock Performance
Shares of NASDAQ:VRTX opened at $477.70 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.52 and a quick ratio of 2.26. Vertex Pharmaceuticals Incorporated has a 1 year low of $341.90 and a 1 year high of $510.64. The firm has a market capitalization of $123.27 billion, a PE ratio of 31.00 and a beta of 0.40. The business’s 50 day moving average price is $475.60 and its 200-day moving average price is $461.36.
Analyst Ratings Changes
VRTX has been the topic of a number of analyst reports. TD Cowen lifted their price objective on shares of Vertex Pharmaceuticals from $450.00 to $500.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Canaccord Genuity Group boosted their target price on shares of Vertex Pharmaceuticals from $371.00 to $376.00 and gave the stock a “sell” rating in a research report on Wednesday, July 31st. Morgan Stanley raised their price target on shares of Vertex Pharmaceuticals from $462.00 to $474.00 and gave the stock an “equal weight” rating in a report on Tuesday, October 1st. Piper Sandler boosted their price objective on shares of Vertex Pharmaceuticals from $500.00 to $535.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Finally, Royal Bank of Canada reduced their target price on Vertex Pharmaceuticals from $431.00 to $425.00 and set a “sector perform” rating for the company in a research note on Friday, October 4th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $492.92.
Read Our Latest Stock Report on VRTX
Insider Activity at Vertex Pharmaceuticals
In other news, Director Sangeeta N. Bhatia sold 646 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the transaction, the director now directly owns 4,435 shares in the company, valued at $2,217,500. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, Director Bruce I. Sachs sold 5,295 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $508.00, for a total value of $2,689,860.00. Following the completion of the sale, the director now owns 40,000 shares of the company’s stock, valued at $20,320,000. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Sangeeta N. Bhatia sold 646 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the sale, the director now owns 4,435 shares of the company’s stock, valued at $2,217,500. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,005 shares of company stock valued at $5,988,066. Corporate insiders own 0.20% of the company’s stock.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Featured Articles
- Five stocks we like better than Vertex Pharmaceuticals
- How to Find Undervalued Stocks
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Overbought Stocks Explained: Should You Trade Them?
- MarketBeat Week in Review – 10/21- 10/25
- Market Cap Calculator: How to Calculate Market Cap
- Texas Roadhouse Stock Steering for New Highs This Year
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.